Rallybio Corporation (RLYB) Dividend History

Company News

• Here's Why Shares in Recursion Pharmaceuticals Surged Today

  Recursion Pharmaceuticals acquired full ownership of REV102, an ENPP1 inhibitor program for treating hypophosphatasia, from Rallybio, reducing pipeline uncertainty and potentially adding value to its drug development efforts.

  The Motley Fool

  Featured Companies: RXRX
• Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

  Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.

  Benzinga

  Featured Companies: RXRX
• RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

  RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.

  Zacks Investment Research

  Featured Companies: ANVS FGEN JNJ
• Spotting Penny Stocks Trading Trends

  Here's 3 tips for spotting penny stocks trends The post Spotting Penny Stocks Trading Trends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: SOUN TPET
• 5 Russell 2000 Stocks Poised to Give the Large Caps a Run for Their Money

  Investing.com

  Featured Companies: CMPX KPTI TNYA VOR